HCBK Ex-Dividend Reminder - 5/10/13

Looking at the universe of stocks we cover at Dividend Channel, on 5/10/13, Hudson City Bancorp, Inc. (HCBK) will trade ex-dividend, for its quarterly dividend of $0.04, payable on 5/30/13. As a percentage of HCBK's recent stock price of $8.44, this dividend works out to approximately 0.47%.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for HCBK, showing historical dividends prior to the most recent $0.04 declared by Hudson City Bancorp, Inc.:

HCBK+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from HCBK is likely to continue, and whether the current estimated yield of 1.90% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of HCBK shares, versus its 200 day moving average:

Hudson City Bancorp, Inc. 200 Day Moving Average Chart

Looking at the chart above, HCBK's low point in its 52 week range is $5.69 per share, with $8.82 as the 52 week high point — that compares with a last trade of $8.44.

According to the ETF Finder at ETF Channel, HCBK makes up 2.40% of the SPDR S&P Bank ETF ( KBE) which is trading lower by about 0.5% on the day Wednesday.

In Wednesday trading, Hudson City Bancorp, Inc. shares are currently up about 0.1% on the day.

null

More from Stocks

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Why Spotify Is the Ultimate Speculative Stock to Buy

Why Spotify Is the Ultimate Speculative Stock to Buy

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data